BI 443651

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

AsthmaCystic FibrosisHealthy

Phase 1

To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers

CompletedNCT02706925

Boehringer IngelheimHealthy

Start: 2016-03-22End: 2016-06-13Updated: 2020-01-02

BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects

CompletedNCT02976519

Boehringer IngelheimCystic Fibrosis

Start: 2017-02-15End: 2018-08-29Updated: 2019-11-27

BI 443651 Methacholine Challenge

CompletedNCT03135899

Boehringer IngelheimAsthma

Start: 2017-05-18End: 2018-02-21Updated: 2019-11-27

Related Papers

First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

ERJ Open Research2020-12-109 citations